Monash IVF (ASX:MVF) Rejects A$0.90 Soul Patt's Bid; Shares Slide 6% on Second Knockback

Monash IVF Group (ASX:MVF) shares slid 6% to A$0.72 on Monday after the board rejected a revised A$0.90 per share takeover bid from a consortium led by Genesis Capital and Washington H. Soul Pattinson (ASX:SOL). This is the second rejection in five months, following an earlier A$0.80 offer in November 2025 that was withdrawn before returning 12.5% higher. With the offer deadline closing today, here is the puzzle: rejecting a higher bid would normally push shares up. Instead, investors are selling. So what is the market really telling us?

Why the Board Says A$0.90 Still Undervalues Monash IVF

The board's reasoning is straightforward. Chair Richard Davis says the offer sits at a "substantial discount to comparable IVF transactions" in Australia. The benchmark the board is anchoring to is the 2022 takeover of rival Virtus Health, which was struck at a meaningfully higher multiple of earnings than what the consortium is offering today.

The board has also pointed to FY25 numbers that show the underlying business is still functioning. Revenue grew, EBITDA grew, but profit fell, largely reflecting the impact of last year's embryo incidents. Importantly, the company recently paid a modest interim dividend in early April, an early signal that management is signalling recovery, even though the FY25 final dividend was suspended. CEO Dr Victoria Atkinson, who took the helm in January and is now nearly four months into the role, has the board's full support for her turnaround strategy.

Our view: the Virtus comparison may no longer hold. The independent review by Fiona McLeod AO SC concluded the incidents stemmed from human error and IT system limitations, findings the market has already digested. The board's confidence may be anchored to pre-crisis valuations that the market has moved past.

‍

What the Market Is Really Telling Us

The share price slide is the real signal here. With the stock at A$0.72, well below the rejected A$0.90 offer, investors clearly do not believe a higher bid is coming.

The consortium's language reinforces this. Calling A$0.90 their "highest amount" absent a competing offer reads as a walk-away line, not a negotiation opener. Soul Patts already owns close to one-fifth of Monash IVF and has not been lifting that stake aggressively. With the deadline closing today, there is no realistic window for a sweetened bid.

Without takeover support, Monash IVF has to stand on its own. That is a tougher case. Reputational damage from the embryo incidents lingers; last year's class action settlement drained cash; the FY25 final dividend was suspended; and patient volumes are still under pressure.

Our view: without a takeover floor under the share price, fair value likely sits closer to current levels until the company can show real operational recovery.

The Investor's Takeaway for MVF

Three scenarios from here:

1. A sweetened bid: possible, but the consortium's "final offer" language suggests it is unlikely.
2. Standalone turnaround under new CEO: credible long-term, but Dr Atkinson still needs more time to demonstrate proof points.
3. Drift back towards pre-bid levels: the most likely near-term outcome.

For existing holders, the rejection removes the near-term catalyst. The thesis is no longer takeover speculation; it is execution. For new buyers, waiting for today's deadline to pass and the dust to settle may offer a cleaner entry point.

The board is playing a confident hand. The market is pricing scepticism. From here, operational performance matters more than deal speculation.

For deeper analysis of ASX healthcare and small-cap M&A situations, ASR's Investing Report covers high-conviction opportunities with detailed risk frameworks. New readers can also start with our free Top-3 Stocks & Market Outlook Report for current ASX ideas and broader market context.

‍